• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment.卵巢低反应难题:从诊断到治疗
Diagnostics (Basel). 2020 Sep 11;10(9):687. doi: 10.3390/diagnostics10090687.
2
Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why.界定接受辅助生殖技术的低预后患者:POSEIDON标准——原因
Front Endocrinol (Lausanne). 2018 Aug 17;9:461. doi: 10.3389/fendo.2018.00461. eCollection 2018.
3
Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept.体外受精中卵巢低反应管理的最新进展:从博洛尼亚标准到波塞冬概念的转变
Ther Adv Reprod Health. 2020 Jul 31;14:2633494120941480. doi: 10.1177/2633494120941480. eCollection 2020 Jan-Dec.
4
Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification.在波塞冬分类背景下用于识别低反应者的卵巢储备标志物
Front Endocrinol (Lausanne). 2019 May 8;10:281. doi: 10.3389/fendo.2019.00281. eCollection 2019.
5
Management Strategies for POSEIDON Groups 3 and 4.波塞冬3组和4组的管理策略
Front Endocrinol (Lausanne). 2019 Sep 11;10:614. doi: 10.3389/fendo.2019.00614. eCollection 2019.
6
Androgens Profile in Blood Serum and Follicular Fluid of Women With Poor Ovarian Response During Controlled Ovarian Stimulation Reveals Differences Amongst POSEIDON Stratification Groups: A Pilot Study.控制性卵巢刺激过程中卵巢反应不良女性血清和卵泡液中的雄激素谱揭示了波塞冬分层组之间的差异:一项初步研究。
Front Endocrinol (Lausanne). 2019 Jul 16;10:458. doi: 10.3389/fendo.2019.00458. eCollection 2019.
7
The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome.辅助生殖技术中“低预后患者”的新型波塞冬分层及其成功结局的提议标志物。
F1000Res. 2016 Dec 23;5:2911. doi: 10.12688/f1000research.10382.1. eCollection 2016.
8
Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept.用于辅助生殖技术中低预后患者的诊断和管理的新方法:POSEIDON 概念。
Panminerva Med. 2019 Mar;61(1):24-29. doi: 10.23736/S0031-0808.18.03511-5. Epub 2018 Jul 18.
9
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.ESHRE 共识:体外受精卵巢刺激反应不良的定义:博洛尼亚标准。
Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.
10
Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.重组人促卵泡激素α/重组人促黄体生成素α在辅助生殖技术中的疗效与安全性:一项针对卵巢反应不良患者的随机对照试验。
Hum Reprod. 2017 Mar 1;32(3):544-555. doi: 10.1093/humrep/dew360.

引用本文的文献

1
Evaluation of gonadotropin-releasing hormone agonist and antagonist protocols on pregnancy outcomes in POSEIDON groups 3 and 4: A randomized controlled trial.评估促性腺激素释放激素激动剂和拮抗剂方案对波塞冬3组和4组妊娠结局的影响:一项随机对照试验。
Int J Reprod Biomed. 2025 Jun 10;23(3):241-250. doi: 10.18502/ijrm.v23i3.18775. eCollection 2024 Apr.
2
Whole-transcriptome sequencing reveals the effects of acupuncture on early embryos post-IVF-ET in poor ovarian response.全转录组测序揭示针刺对卵巢反应不良患者体外受精-胚胎移植后早期胚胎的影响。
J Ovarian Res. 2025 Apr 30;18(1):91. doi: 10.1186/s13048-025-01682-7.
3
Intra-ovarian injection of autologous menstrual blood-derived-mesenchymal stromal cells: a safe and promising method to improve pregnancy rate in poor ovarian responders.卵巢内注射自体月经血来源的间充质基质细胞:一种提高卵巢反应不良患者妊娠率的安全且有前景的方法。
Stem Cell Res Ther. 2025 Apr 12;16(1):171. doi: 10.1186/s13287-025-04278-6.
4
The Effectiveness of the GnRH Agonist/Antagonist Protocols for Different Poseidon Subgroups of Poor Ovarian Responders.促性腺激素释放激素激动剂/拮抗剂方案对不同波塞冬亚组卵巢低反应者的有效性
J Clin Med. 2025 Mar 17;14(6):2026. doi: 10.3390/jcm14062026.
5
Pretreatment with oral contraceptives benefit POSEIDON group 1 low prognosis patients during GnRH-antagonist protocol: a propensity score-matched retrospective cohort study.口服避孕药预处理对 GnRH 拮抗剂方案中 POSEIDON 组 1 低预后患者有益:一项倾向评分匹配的回顾性队列研究。
J Ovarian Res. 2025 Mar 7;18(1):47. doi: 10.1186/s13048-025-01613-6.
6
Analysis of the day 3 transfer strategy for POSEIDON patients.POSEIDON患者第3天移植策略分析。
JBRA Assist Reprod. 2025 Feb 21;29(2):298-305. doi: 10.5935/1518-0557.20240111.
7
Metabolomics-Driven Insights into Biomarkers for Poor Ovarian Response: A Narrative Review.代谢组学驱动的卵巢反应不良生物标志物研究见解:一项叙述性综述
Biomedicines. 2025 Jan 16;13(1):214. doi: 10.3390/biomedicines13010214.
8
Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial.虾青素通过减轻氧化应激、炎症和细胞凋亡改善卵巢反应不良患者的辅助生殖技术结局:一项随机临床试验。
J Ovarian Res. 2024 Oct 31;17(1):212. doi: 10.1186/s13048-024-01537-7.
9
The impact of the embryo banking on the cumulative live birth rate in women with poor ovarian response according to the Bologna criteria.根据博洛尼亚标准,胚胎库对卵巢反应不良女性累积活产率的影响。
Reprod Med Biol. 2023 Aug 26;22(1):e12533. doi: 10.1002/rmb2.12533. eCollection 2023 Jan-Dec.
10
"Short agonist stop" protocol, an ovarian stimulation for poor responders in fertilization (IVF): A pilot study."短激动剂阻断"方案在体外受精(IVF)中对卵巢低反应患者的促排卵:一项初步研究。
Front Endocrinol (Lausanne). 2022 Nov 17;13:1056520. doi: 10.3389/fendo.2022.1056520. eCollection 2022.

本文引用的文献

1
Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women.通过自体富血小板血浆卵巢内输注恢复卵巢功能:关于卵巢早衰、围绝经期、绝经后及低反应性女性的初步数据
J Clin Med. 2020 Jun 10;9(6):1809. doi: 10.3390/jcm9061809.
2
Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates.根据博洛尼亚标准,卵巢低反应患者的异质性导致累积活产率出现差异。
Front Endocrinol (Lausanne). 2020 Apr 16;11:208. doi: 10.3389/fendo.2020.00208. eCollection 2020.
3
What Is the Best Regimen for Ovarian Stimulation of Poor Responders in ART/IVF?ART/IVF 中卵巢刺激不良反应者的最佳方案是什么?
Front Endocrinol (Lausanne). 2020 Apr 17;11:192. doi: 10.3389/fendo.2020.00192. eCollection 2020.
4
Preimplantation genetic testing for aneuploidy in poor ovarian responders with four or fewer oocytes retrieved.对卵巢反应不良患者(取卵数为 4 个或更少)进行胚胎植入前染色体非整倍体检测。
J Assist Reprod Genet. 2020 May;37(5):1147-1154. doi: 10.1007/s10815-020-01765-y. Epub 2020 Apr 13.
5
Assessing the practice of LuPOR for poor responders: a prospective study evaluating follicular fluid cfDNA levels during natural IVF cycles.评估 LuPOR 在卵巢低反应患者中的应用:一项评估自然 IVF 周期中卵泡液 cfDNA 水平的前瞻性研究。
J Assist Reprod Genet. 2020 May;37(5):1183-1194. doi: 10.1007/s10815-020-01743-4. Epub 2020 Mar 27.
6
Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis.辅助治疗策略在 IVF 中对卵巢刺激反应不良者的应用:系统评价和网络荟萃分析。
Hum Reprod Update. 2020 Feb 28;26(2):247-263. doi: 10.1093/humupd/dmz046.
7
The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study.自身富含血小板血浆(PRP)与不干预在卵巢储备功能低下的接受生育治疗的女性中的应用:一项非随机干预研究。
J Assist Reprod Genet. 2020 Apr;37(4):855-863. doi: 10.1007/s10815-020-01710-z. Epub 2020 Feb 7.
8
The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists.从临床医生和胚胎学家的视角看POSEIDON标准及其成功衡量指标
Front Endocrinol (Lausanne). 2019 Nov 20;10:814. doi: 10.3389/fendo.2019.00814. eCollection 2019.
9
Autologous mitochondrial microinjection; a strategy to improve the oocyte quality and subsequent reproductive outcome during aging.自体线粒体显微注射:一种改善衰老过程中卵母细胞质量及后续生殖结局的策略。
Cell Biosci. 2019 Nov 29;9:95. doi: 10.1186/s13578-019-0360-5. eCollection 2019.
10
What is the true place of a double stimulation and double oocyte retrieval in the same cycle for patients diagnosed with poor ovarian reserve? A systematic review including a meta-analytical approach.对于被诊断为卵巢储备功能不良的患者,在同一个周期内进行双重刺激和双重取卵的真正位置是什么?一项包括荟萃分析方法的系统评价。
J Assist Reprod Genet. 2020 Jan;37(1):181-204. doi: 10.1007/s10815-019-01638-z. Epub 2019 Dec 3.

卵巢低反应难题:从诊断到治疗

The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment.

作者信息

Giannelou Polina, Simopoulou Mara, Grigoriadis Sokratis, Makrakis Evangelos, Kontogeorgi Adamantia, Pantou Agni, Galatis Dionysios, Kalampokas Theodoros, Bakas Panagiotis, Bolaris Stamatis, Pantos Konstantinos, Sfakianoudis Konstantinos

机构信息

Department of Physiology, Medical School, National and Kapodistrian University of Athens, 75, Mikras Asias, 11527 Athens, Greece.

Centre for Human Reproduction, Genesis Athens Clinic, 14-16, Papanikoli, 15232 Athens, Greece.

出版信息

Diagnostics (Basel). 2020 Sep 11;10(9):687. doi: 10.3390/diagnostics10090687.

DOI:10.3390/diagnostics10090687
PMID:32932955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7555981/
Abstract

Despite recent striking advances in assisted reproductive technology (ART), poor ovarian response (POR) diagnosis and treatment is still considered challenging. Poor responders constitute a heterogeneous cohort with the common denominator of under-responding to controlled ovarian stimulation. Inevitably, respective success rates are significantly compromised. As POR pathophysiology entails the elusive factor of compromised ovarian function, both diagnosis and management fuel an ongoing heated debate depicted in the literature. From the criteria employed for diagnosis to the plethora of strategies and adjuvant therapies proposed, the conundrum of POR still puzzles the practitioner. What is more, novel treatment approaches from stem cell therapy and platelet-rich plasma intra-ovarian infusion to mitochondrial replacement therapy have emerged, albeit not claiming clinical routine status yet. The complex and time sensitive nature of this subgroup of infertile patients indicates the demand for a consensus on a horizontally accepted definition, diagnosis and subsequent effective treating strategy. This critical review analyzes the standing criteria employed in order to diagnose and aptly categorize POR patients, while it proceeds to critically evaluate current and novel strategies regarding their management. Discrepancies in diagnosis and respective implications are discussed, while the existing diversity in management options highlights the need for individualized management.

摘要

尽管辅助生殖技术(ART)近年来取得了显著进展,但对卵巢低反应(POR)的诊断和治疗仍被认为具有挑战性。卵巢低反应者是一个异质性群体,其共同特征是对控制性卵巢刺激反应不足。不可避免地,各自的成功率会受到显著影响。由于POR的病理生理学涉及卵巢功能受损这一难以捉摸的因素,其诊断和管理在文献中引发了持续激烈的争论。从用于诊断的标准到提出的众多策略和辅助治疗方法,POR的难题仍然困扰着从业者。此外,从干细胞治疗、富血小板血浆卵巢内注射到线粒体替代疗法等新型治疗方法已经出现,尽管尚未声称具有临床常规地位。这类不孕患者群体的复杂性和时间敏感性表明,需要就横向认可的定义、诊断及后续有效治疗策略达成共识。这篇批判性综述分析了用于诊断和恰当分类POR患者的现有标准,同时对当前及新型管理策略进行了批判性评估。讨论了诊断中的差异及其各自的影响,而现有管理方案的多样性凸显了个体化管理的必要性。